story is that this autocrine loop turns on these pathways constitutively; this begs the question, 'Do other oncogenes follow similar strategies in activating this normal cellular control hierarchy?'
The elucidation of the sequence of the epidermal growth factor receptor (EGF-R) has revealed that a truncated version ofthis transmembrane polypeptide has been picked up by an avian virus to produce the v-erb B transforming gene. While no formal proof exists, this implies that this truncated polypeptide functions as an activated growth factor receptor (i.e. as a ligand bound receptor) in an uncontrolled manner. Similarly, there are recent data indicating that CSF-1 receptor is the cellular homologue of the v-fms transforming protein. Thus oncogenes may undermine the function of proteins that are normally involved in controlling cell proliferation.
It is not clear how far down the normal growth control hierarchy that this strategy for transformation occurs. It is clear, however, that post-receptor pathways are very complex and elucidation of these transducing pathways will be of great interest in terms of our understanding of uncontrolled proliferation.
Nerve growth factor
Professor Charles Vernon (University College Hospital, London) commented that the existence of a factor essential for nerve outgrowth in chick embryos has been known for many years. The factor is a glycoprotein with a molecular weight below Journal of the Royal Society of Medicine Volume 80 September 1987 593 100000. Interestingly, in parallel to the action of CSF, it is essential not only for the growth but also continued survival of neural tissue. Its precise structure and physiological role remain largely undefined.
Conclusions
Haemopoiesis, in particular, has provided a rich field of investigation into the nature and properties of growth factors. These studies point to the possibility that specific growth factors are necessary for a number of functions, including cell survival as well as cell proliferation and development. Their specificity and mode of action are linked directly to the presence of specific surface receptors on the target cell, and their mechanism of action within the cell cytoplasm and nucleus may therefore share a final common pathway. Thus, investigation into the mode of action of specific growth factors such as CSF may provide fundamental information relevant to the action of other growth factors. In addition, our understanding of physiological growth factors has shed light on the very similar role that oncogenes may play in causing abnormal growth in malignant processes.
AJBarrett
Immediate Past President Section of Pathology (Accepted 9 September 1986) New concepts in vaccination Keywords: vaccines, viruses, recombinants, adjuvants, immune system The November 1986 meeting of the Section of Comparative Medicine had as its theme, 'New concepts in vaccination'. The first speaker, Dr A J Beale (Wellcome Biotechnology), gave a brief summary of old and new ideas about protective vaccination. Dr Edward Jenner made the first semi-scientific attempt to develop a vaccine with his development of the cowpox vaccine and the idea of using live attenuated organisms as vaccines was formally introduced by Louis Pasteur. Dr Glenny (Wellcome) had been a further pioneer in the history of vaccine production by highlighting the difference between the primary and secondary immune response, introducing formalin for toxoiding diphtheria and tetanus toxins and to preserve immunogenicity, and very importantly, by introducing aluminium salts as immunostimulating adjuvants. Dr Beale also mentioned the survey of 1000 families carried out in Newcastle-Upon-Tyne shortly after the Second World War, in which children were followed up from birth for 20 years in an effort to study the pattern of infectious diseases such as whooping cough and to show the immunizing effect of these infections in the general population. Professor J W Almond (Reading University) spoke of his studies of the neurovirulence of polio-viruses and the prospects for new vaccines. Although the incidence of poliomyelitis had declined rapidly after the introduction of,first, the inactivated vaccine (Salk), and then the live attenuated oral vaccine (Sabin), WHO still reports an incidence of at least 500000 cases of polio a year, thus highlighting the need for a new and more effective vaccine. Work has concentrated on the serotype 3 poliovirus, which is most often implicated in cases of paralysis in vaccinees. The neurovirulent parent strain (P3/ Leon/37) was isolated from the brain and spinal cord of a fatal case of polio. After passage through monkey tissue, the Leon progenitor and then the P3/Sabin vaccine was obtained. A revertant strain P3/119 had a high virulence score, as did the Leon progenitor. The Sabin vaccine strain had a very low virulence score, it was easy to administer to large populations and was thus cost-effective and the most widely used polio vaccine. A study on passage in man of the Sabin vaccine strain had revealed excretion ofa virus with a greatly increased histological lesion score, indicating rapid selection and/or reversion for a neurovirulent strain by growth in the human gut. A series of recombinants has been found in the pathway between the parent P3/Leon/37 and P3/Sabin strains. Two mutations at base positions 472 and 2034 contribute to attentuation. Similarly, changes at base position 480 (next position to 472 in serotype 3) have been found to occur during the production of the type 1 vaccine strain (Sabin 1) from its virulent progenitor Mahoney. New approaches to the development of a more effective vaccine have been facilitated by Report of meeting of Section of Comparative Medicine, 19 November 1986 0141-0768/87/ 090593-03/$02.00/0 4:)1987
The Royal Society of Medicine construction of a three-dimensional model of the poliovirus. An attempt at directed genetic engineering of the virus is possible. Now that the scourge ofsmallpox has been virtually eradicated, Dr G L Smith (Cambridge University) explained, thoughts are turning to new uses for the old vaccine strain of vaccinia virus, including development of a live recombinant vaccinia virus offering protection against smallpox and other pa tho gens. The production of a recombinant virus involves construction in vitro of a chimaeric gene, by joining a vaccinia promoter to a foreign protein coding sequence in a plasmid vector. The chimaeric gene is flanked with DNA from a non-essential vaccinia gene, such as thymidine kinase. The chimaeric gene is then inserted into the vaccinia virus by homologous recombination in infected cells. The recombinant is selected by virtue ofits thymidine kinase-negative phenotype. Insertion of DNA in this way into various parts of the vaccinia virus has not affected its replication and the productof the gene has been detected immunologically.
Examples of situations where the recombinant vaccinia virus could be used as a vaccine against pathogens from which the gene is derived include hepatitis B virus infection and falciparum malaria. Cloning genes in vaccinia virus can also be used to identify potential protective antigens from other pathogens, especially in circumstances where no effective vaccine has yet been developed. Citing the example of the human cytomegalic disease and influenza viruses, Dr Smith outlined how a recombinant vaccinia virus incorporating a foreign antigen could be developed and thereafter used in animals to stimulate recognition of a foreign antigen. In the case of human cytomegalic disease virus, this would be achieved by the production of neutralizing antibodies. For influenza virus, cells infected with the recombinant vaccinia virus would be recognized and lysed by cytotoxic Tlymphocytes.
The disadvantages of using live vaccinia virus recombinants as vaccines include a potential change in virus tropism or pathogenicity, and the degree of immunity to vaccinia in the adult population. Advantages include stimulation both of antibody and cell-mediated responses to the host and the large capacity of the virus for foreign DNA with simultaneous expression of multiple antigens. Such vaccines should also be cheap and simple to produce and would be as stable as the freeze-dried preparation. They may have a wide range of applications both in the medical and veterinary fields.
Dr F Brown (Wellcome Biotechnology) discussed peptides as the next generation of virus vaccines, taking as an example foot and mouth disease virus. This single-stranded RNA virus contains four proteins. Virus protein 1 (VP 1) is important in stimulation of the immune response. The antigenic sites on VP 1 can be determined by various methods, including the classical chemical technique of cleaving the protein using enzymes and studying the fragments obtained. Another method involves relating antigenic variation to amino acid sequence variation in naturally occurring and laboratory-derived variants. Experiments have shown that a single-dose inoculation of the peptide vaccine against foot and mouth disease was sufficient to protect guineapigs against challenge with live virus. Using peptide vaccines can also provide protection against a broader spectrum of infection (i.e, against more than one strain of the virus) by insertion or deletion of particular amino acids.
Amongst the many probable advantages of using peptide vaccines are that they should be stable indefinitely if kept dry, no large-scale production plant or downstream processing would be required and they are not infectious. Furthermore, they can be designed to produce just the required immune response and could provide an opportunity to enhance the response by using a delayed-release preparation. Peptide vaccines show great potential for the future, although they remain an expensive and so far only putative alternative at present.
The possible effectiveness of a polyvalent/bivalent vaccine over the existing monovalent vaccine against Marek's disease in the chicken was discussed by Dr P C Powell (Houghton Poultry Research Station). Effective live vaccines were produced against the causal herpesvirus in the early 1970s,which afforded a protection rate of 94%. Failure to protect fully against the disease is ascribed to a number of factors, including faulty manufacture, using an incorrect dose of the vaccine, change in field strains of the virus and the effects of stress in the host. The emergence of multiple field strains leads to large fluctuations in the seasonal incidence of the disease. It may be due to mutation or selection pressure even by uncommon pre-existing strains.
The answer to more effective control of the disease lies in producing a more resistant breed of chicken or, alternatively, in the development of a new vaccine with increased efficacy against the disease. Three serotypes of the virus exist. The prototype virulent strain is serotype 1, and serotypes 2 and 3 are a nonpathogenic Marek's disease virus of chickens and a non-pathogenic herpesvirus of turkeys, respectively. Field trials have shown that combinations of two or more attenuated versions of the serotypes, i.e, a bivalent or polyvalent vaccine, afford good protection. There is no explanation as yet for the synergistic effect of vaccines from the different serotypes as there is very little DNA homology between them. A new approach towards control of the disease may lie in development of an inexpensive attenuated synthetic vaccine with desirable qualities from all three serotypes, which would give better protection than the monovalent vaccine, especially against the more virulent strains.
G Dougan (Wellcome Biotechnology) spoke on live attenuated bacterial vaccines for protection against enteric pathogens. He concentrated on salmonella mutants as vectors. The genes responsible for key metabolic enzymes are deleted, allowing the bacterium to infect target organs, such as macrophages and other immune system cells, without causing clinical disease but inducing humoral and cellular immune responses. A variety of antigens can be incorporated into salmonella mutants to create a double vaccine. Toxoids, mycobacterial antigens, parasite antigens, peptides and polysaccharides are all under investigation. Plasmids carrying the cholera toxin LTB gene have recently been incorporated into a mutant and have elicited neutralizing antibodies when given orally. ' The problems of immune recognition of the influenza haemagglutinin were described by Dr J J Skehel (Medical Research Council, Mill Hill). The haemagglutinin and neuraminidase glycoproteins in the virus membrane are responsible for the anti-genic variation of the virus. Neutralizing antibodies appear to act specifically against the haemagglutinins, particularly the distal region, which contains five antigenically important surface epitopes surrounding a conserved region that represents the receptor binding site. The main problem with vaccine development is that the important epitopes differ between virus variants and humoral cross-immunity is poor. There is some hope that peptides based on better conserved areas of haemagglutinins may be able to produce good cellular immune response.
The importance of immune stimulation of mucosal surfaces was outlined by Professor F J Bourne (Bristol Veterinary School). Many pathogens enter the body via mucosae and systemic vaccination is often not protective for the diseases they cause. Mucosal vaccines mimic the pathogen entry route and are more effective. Also, oral vaccines are easier to administer in many food animal production regimens. Mucosally presented antigen can stimulate systemic humoral and cellular immunity as well as local immunity, and can also provide some protection for distant mucosal sites via the common mucosal system. Complex protection mechanisms depending largely on IgA and suppressor T-cells exist in the gut to prevent wasteful or harmful immune responses to dietaryantigens. Vaccine antigens need to be presented in a special way to avoid induction of tolerance. Previously, it was thought that all antigens processed by the gut immune system were sampled via the Peyer's patches. Recent studies have shown that the enterocyte can express class 2 MHC antigen and process and present foreign antigen to T-cells.
Professor E J L Soulsby (Cambridge Veterinary School) described factors in unresponsiveness to parasite vaccines. The measured immune response is often good, but parasites have evolved many mechanisms of evasion. Young animals often produce a poorer immune response than adults and so are most affected by such diseases. Pregnancy, parturition and lactation have all been shown to reduce the host immune response against gastrointestinal nematodes. In sheep, this allows the parasites to mature and results in an increased contamination of the pasture with-eggs, which subsequently affect the lambs. In addition, parasites in the gut of the ewe produce suppressor factors, which are transferred to the lamb via the colostrum. He postulated that these factors induce a suppressor T-cell population in the lamb, which makes vaccination ineffective, and which may persist until 14-16 weeks of age. Future research would concentrate on investigating the suppressor factors and on identifying helminth antigens which could be protective for the neonate.
Mr D Danson (Duphar Ltd) outlined the problems of getting a vaccine onto the veterinary market. The economic climate is of a stagnant agricultural market and increased competition, and scientific research is being carefully tailored to meet the veterinary and commercial needs of the customer. A range of vaccines exist or are in development, including live, inactivated, subunit, synthetic and anti-idiotype preparations. Each has to be evaluated on the grounds of efficacy, safety and cost. The new generation of recombinant DNA vaccines, such as deletion mutants and the live herpes and vaccinia recombinant carriers, are cheap and effective, but their safety is unknown. It might be better to concentrate on the development of subunit and synthetic vaccines rather Journal ofthe RoyalSocietyofMedicine Volume 80 September1987 595 than risk the release oflive engineered organisms into the environment.
Adjuvants were reviewed by Professor J H L Playfair (Middlesex Hospital Medical School). As potential vaccine antigens are getting smaller in molecular size and so have less immunogenicity, the need for effective adjuvants is increasing. Vehicles such as Iiposomes, iscoms and pluronic polyols, and physiological agents such as interleukin 1, gammainterferon and Ig M, have all been shown to have adjuvant properties, as well as the established depot, bacterial and bacterial derivatives. Side effects are an important consideration with adjuvants, such as granuloma formation with aluminium hydroxide and fever with gamma-interferon and interleukin l. Autoimmunity seems not to be a clinical problem even with good adjuvants. The mechanism of adjuvant activity is probably the increased expression of class 2 MHC antigens and increased interleukin 1 production, both of which have fundamental effects on antigen presentation and immune cell activation.
A wide range of topics was covered at the meeting and left no doubt that this, the oldest type of preventive medicine, has now become the site of new scientific ferment.
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Society news
Clinical Endocrinology Trust/Royal Society of Medicine Visiting Professor
The Clinical Endocrinology Trust was founded in 1983by the journal Clinical Endocrinology under the chairmanship of Sir John Nabarro, and amongst its other activities the Trust annually sponsors a Visiting Professor for the Section of Endocrinology of the RSM. This year's Professorship was awarded to K J Catt, from the National Institute of Health, USA, who visited the UK for 3 weeks in March 1987. In a hectic schedule he visited endocrine centres in 7 cities outside London and 6 endocrine centres in London, as well as attending the 7th National Meeting of British Endocrine Societies, at which he delivered a plenary lecture entitled 'Receptoractivated mechanisms of peptide hormone action'. This was attended by nearly 600 people, and was a masterly review of the post-receptor mechanisms
